E
Elizabeth Adams
Researcher at National Institutes of Health
Publications - 27
Citations - 5060
Elizabeth Adams is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Vaccination & Dermatomyositis. The author has an hindex of 19, co-authored 26 publications receiving 4772 citations. Previous affiliations of Elizabeth Adams include Henry M. Jackson Foundation for the Advancement of Military Medicine.
Papers
More filters
Journal ArticleDOI
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more
TL;DR: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk and offer insight for future research.
Journal ArticleDOI
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer,Magdalena E. Sobieszczyk,Holly Janes,Shelly Karuna,Mark J. Mulligan,Doug Grove,Beryl A. Koblin,Susan Buchbinder,Michael C. Keefer,Georgia D. Tomaras,Nicole Frahm,John Hural,Chuka Anude,Barney S. Graham,Mary E. Enama,Elizabeth Adams,Edwin DeJesus,Richard M. Novak,Ian Frank,Carter Bentley,Shelly Ramirez,Rong Fu,Richard A. Koup,John R. Mascola,Gary J. Nabel,David C. Montefiori,James G. Kublin,M. Juliana McElrath,Lawrence Corey,Peter B. Gilbert +29 more
TL;DR: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied and had an acceptable side-effect profile.
Journal ArticleDOI
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.
David A. Isenberg,Elizabeth Allen,Vernon T. Farewell,M. Ehrenstein,Michael G. Hanna,I.E. Lundberg,C. Oddis,Clarissa Pilkington,P. H. Plotz,D. L. Scott,Jiri Vencovsky,Rachel Cooper,Lisa G. Rider,Frederick W. Miller,Elizabeth Adams,Helene Alexanderson,Nancy Armentrout,Zohar Argov,Richard J. Barohn,Suzanne L. Bowyer,Hermine I. Brunner,Rubén Burgos-Vargas,Jeffrey P. Callen,Gail Cawkwell,Patrick Cherin,Yuen-Li Chung,Hanna Chwalińska-Sadowska,Robert D. Cooper,Cronin Me,Katarina Danko,Joyce Davidson,Peter B. Dent,Elizabeth M. Dugan,Brian M. Feldman,Richard Finkel,Ignacio García-De La Torre,Ekkehard Genth,Edward H. Giannini,Gerald J D Hengstman,Jeanne E. Hicks,Adam M. Huber,Hans Iko Huppertz,Lisa Imundo,Kent J. Johnson,Joseph L. Jorizzo,Lawrence Kagen,John T. Kissel,Marisa S. Klein-Gitelman,Abraham Garcia Kutzbach,Bianca Lang,Marissa Lassere,Carol B. Lindsley,Daniel J. Lovell,Sue Maillard,Peter N. Malleson,Alberto Martini,Thomas A. Medsger,Kevin J. Murray,Chester V. Oddis,Lauren M. Pachman,Amy Paller,Maria D. Perez,Paul H. Plotz,Dieter Pongratz,Angelo Ravelli,Ann M. Reed,Robert M. Rennebohm,Nicolino Ruperto,Seward Rutkove,Clyde Ryder,Jean Luc Senécal,Georges Serratrice,Jacques Serratrice,David Sherry,Kumaraswamy Sivakumar,Yeong Song,Richard D. Sontheimer,Ira N. Targoff,Maria L. Turner,Basiel van Engelen,Maria L. Villalba,Kelly Vincent,Victoria P. Werth,Patience H. White,James Witter,Robert Wortmann,Steven R. Ytterberg +86 more
TL;DR: The MITAX, MYOACT and MDI tools, which are now undergoing validity testing, should enhance the consistency, comprehensiveness and reliability of disease activity and damage assessment in patients with myositis.
Journal ArticleDOI
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
Merlin L. Robb,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Punnee Pitisuttithum,Jaranit Kaewkungwal,Prayura Kunasol,Chirasak Khamboonruang,Prasert Thongcharoen,Patricia Morgan,Michael Benenson,Robert Paris,Joseph Chiu,Elizabeth Adams,Donald P. Francis,Sanjay Gurunathan,Jim Tartaglia,Peter B. Gilbert,Don Stablein,Nelson L. Michael,Jerome H. Kim,Jerome H. Kim +20 more
TL;DR: In this article, the authors performed a post-hoc analysis of the trial's data to investigate behavioural risk and efficacy every 6 months after vaccination, and found that the vaccine efficacy seemed to peak early and declined quickly.
Journal ArticleDOI
Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens
Lourdes Villalba,Jeanne E. Hicks,Elizabeth Adams,Jeffrey B. Sherman,Mark F. Gourley,Richard L. Leff,Bonnie C. Thornton,Suzanne H. Burgess,Paul H. Plotz,Frederick W. Miller +9 more
TL;DR: Combination oral MTX/AZA may benefit patients with treatment-resistant myositis, including those who previously had inadequate responses to either MTX or AZA alone, and I.V. MTX with leucovorin rescue may also benefit some patients with refractoryMyositis.